Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Mar 18:16:72.
doi: 10.1186/s12888-016-0752-6.

Stop or go? Preventive cognitive therapy with guided tapering of antidepressants during pregnancy: study protocol of a pragmatic multicentre non-inferiority randomized controlled trial

Nina M Molenaar  1 , Marlies E Brouwer  2 , Claudi L H Bockting  2 , Gouke J Bonsel  3 , Christine N van der Veere  4 , Hanneke W Torij  5 , Witte J G Hoogendijk  1 , Johannes J Duvekot  3 , Huibert Burger  6 , Mijke P Lambregtse-van den Berg  7   8   9
Affiliations
Randomized Controlled Trial

Stop or go? Preventive cognitive therapy with guided tapering of antidepressants during pregnancy: study protocol of a pragmatic multicentre non-inferiority randomized controlled trial

Nina M Molenaar et al. BMC Psychiatry. .

Abstract

Background: Approximately 6.2 % of women in the USA and 3.7 % of women in the UK, use Selective Serotonin Reuptake Inhibitors (SSRIs) during their pregnancies because of depression and/or anxiety. In the Netherlands, this prevalence is around 2 %. Nonetheless, SSRI use during pregnancy is still controversial. On the one hand SSRIs may be toxic to the intrauterine developing child, while on the other hand relapse or recurrence of depression during pregnancy poses risks for both mother and child. Among patients and professionals there is an urgent need for evidence from randomized studies to make rational decisions regarding continuation or tapering of SSRIs during pregnancy. At present, no such studies exist.

Methods/design: 'Stop or Go' is a pragmatic multicentre randomized non-inferiority trial among 200 pregnant women with a gestational age of less than 16 weeks who use SSRIs without clinically relevant depressive symptoms. Women allocated to the intervention group will receive preventive cognitive therapy with gradual, guided discontinuation of SSRIs under medical management (STOP). Women in the control group will continue the use of SSRIs (GO). Primary outcome will be the (cumulative) incidence of relapse or recurrence of maternal depressive disorder (as assessed by the Structured Clinical Interview for DSM disorders) during pregnancy and up to three months postpartum. Secondary outcomes will be child outcome (neonatal outcomes and psychomotor and behavioural outcomes up to 24 months postpartum), and health-care costs. Total study duration for participants will be therefore be 30 months. We specified a non-inferiority margin of 15 % difference in relapse risk.

Discussion: This study is the first to investigate the effect of guided tapering of SSRIs with preventive cognitive therapy from early pregnancy onwards as compared to continuation of SSRIs during pregnancy. We will study the effects on both mother and child with a pragmatic approach. Additionally, the study examines cost effectiveness. If non-inferiority of preventive cognitive therapy with guided tapering of SSRIs compared to intended continuation of SSRIs is demonstrated for the primary outcome, this may be the preferential strategy during pregnancy.

Trial registration: Netherlands Trial Register (NTR): NTR4694 ; registration date: 16-jul-2014.

Keywords: Antidepressants; Cognitive therapy; Cost-effectiveness; Depression; Perinatal outcome; Pregnancy; Prevention; Recurrence; Relapse; SSRI; Selective serotonin reuptake inhibitors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study flow chart
See this image and copyright information in PMC

References

    1. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194. doi: 10.1016/j.ajog.2007.07.036. - DOI - PubMed
    1. Charlton RA, Jordan S, Pierini A, Garne E, Neville AJ, Hansen AV, et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG. 2015;122(7):1010–20. doi: 10.1111/1471-0528.13143. - DOI - PubMed
    1. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600–6. doi: 10.1111/j.1365-2125.2007.03048.x. - DOI - PMC - PubMed
    1. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62(10):863–70. doi: 10.1007/s00228-006-0177-0. - DOI - PubMed
    1. Quispel C, Schneider TAJ, Bonsel GJ, Lambregtse-van den Berg MP. An innovative screen-and-advice model for psychopathology and psychosocial problems among urban pregnant women: an exploratory study. J Psychosom Obstet Gynecol. 2012;33(1):7–14. doi: 10.3109/0167482X.2011.649814. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data